Evidence map›Paper›PMID 24920815›Full record

ArticleJournal of virology2014

Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Shin-Hee Kim, Shun Chen, Xi Jiang, Kim Y Green, Siba K Samal

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Shin-Hee KimVirginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
Shun ChenVirginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
Xi JiangDivision of Infectious Disease, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Kim Y GreenLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, DHHS, Bethesda, Maryland, USA.
Siba K SamalVirginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA ssamal@umd.edu.
University of Maryland, College Park · USNational Institutes of Health · USUniversity of Cincinnati · USVirginia–Maryland College of Veterinary Medicine · US

Funding

Noroviruses and Epidemic GastroenteritisZIAAI000897 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GREEN, KIM Y. · 2009 to 2025
$29.6M
Newcastle Disease Virus Vectored Vaccines for Norovirus InfectionR21AI100195 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI SAMAL, SIBA K · 2012 to 2013
$404k
NIAID NIH HHS 1R21AI100195NIAID NIH HHS R21 AI100195
6 · The paper itself

Abstract

unlabelledHuman norovirus infection is the most common cause of viral gastroenteritis worldwide. Development of an effective vaccine is required for reducing norovirus outbreaks. The inability to grow human norovirus in cell culture has hindered the development of live-attenuated vaccines. To overcome this obstacle, we generated a recombinant Newcastle disease virus (rNDV)-vectored experimental norovirus vaccine by expressing the capsid protein (VP1) of norovirus strain VA387. We compared two different NDV vectors, a conventional rNDV vector and a modified rNDV vector, for their efficiencies in expressing VP1 protein. Our results showed that the modified vector replicated to higher titers and expressed higher levels of VP1 protein in DF1 cells and in allantoic fluid of embryonated chicken eggs than did the conventional vector. We further demonstrated that the VP1 protein produced by rNDVs was able to self-assemble into virus-like particles (VLPs) that are morphologically similar to baculovirus-expressed VLPs. Evaluation of their immunogenicity in mice showed that the modified rNDV vector induced a higher level of IgG response than those induced by the conventional vector and by the baculovirus-expressed VLPs. The rNDV vectors predominantly induced IgG2a subclass antibody for the Th1 response, and specifically, high levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-2 (IL-2) were detected in splenocytes. In addition, the modified rNDV vector induced a higher level of fecal IgA response in mice than did baculovirus-expressed VLPs. Our findings suggest that the rNDV vector is an efficient system to produce cost-effective VLPs in embryonated chicken eggs and has the potential to be used as a live-attenuated vaccine in humans. IMPORTANCE: Noroviruses are the major cause of viral gastroenteritis worldwide. Currently, effective vaccines against norovirus infection are not available. In this study, we have evaluated Newcastle disease virus (NDV) as a vaccine vector for norovirus. Our results suggest that NDV can be used not only as a cost-effective method for large-scale production of norovirus-like particle vaccines but also as a live-attenuated vectored vaccine.

Indexed as

Immunity, MucosalAnimalsAntibodies, ViralCapsid ProteinsChick EmbryoChickensCytokinesDrug CarriersFecesFemaleGenetic VectorsImmunoglobulin AImmunoglobulin GLeukocytes, MononuclearMice, Inbred BALB CNewcastle disease virusAntibodies, ViralCapsid ProteinsCytokinesDrug CarriersImmunoglobulin AImmunoglobulin GVaccines, Virus-Like ParticleViral Vaccines

Identifiers

PMID24920815
PMCPMC4136303
OpenAlexW1997642671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.